C. Chollet

Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr‐Abl–positive cells

V. Praloran, F. Mahon, F. Belloc, 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.

C. Preudhomme, J. Reiffers, V. Praloran, 2006, Haematologica.

α-Defensin 1-3 And α-Defensin 4 as Predictive Markers of Imatinib Resistance and Relapse in CML Patients

B. Turcq, J. Reiffers, M. Dupouy, 2011, Disease markers.

Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line

B. Turcq, S. Hayette, I. Tigaud, 2019, Annals of Hematology.

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors

F. Durrieu, B. Turcq, S. Hayette, 2019, Cancer medicine.

Molecular monitoring of patients with ETV6‐PDGFRB rearrangement: Implications for therapeutic adaptation

E. Lippert, A. Delmer, F. Mahon, 2018, British journal of haematology.

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.

J. Melo, F. Moreau-Gaudry, J. Goldman, 2003, Blood.

leukemia cell line models MDR1 gene overexpression confers resistance to imatinib mesylate in

J. Melo, F. Moreau-Gaudry, J. Goldman, 2013 .

Mutation in the ATP‐binding site of BCR‐ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571

C. Barthe, P. Cony-Makhoul, J. Melo, 2002, British journal of haematology.